(5-溴吡啶-2-基)甲基氨基甲酸叔丁酯 | 227939-01-7

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: (5-溴吡啶-2-基)甲基氨基甲酸叔丁酯
• 中文别名: 2-(N-Boc-N-甲基氨基)-5-溴吡啶
• 英文名称: 5-bromo-2-(N-methyl-N-(t-butoxycarbonyl)amino)pyridine
• 英文别名: tert-butyl (5-bromopyridin-2-yl)(methyl)carbamate；tert-butyl(5-bromopyridin-2-yl)(methyl)carbamate；tert-butyl (5-bromopyridin-2-yl)methylcarbamate；tert-butyl 5-bromopyridin-2-yl(methyl)carbamate；2-(N-BOC-N-methylamino)-5-bromopyridine；tert-butyl N-(5-bromopyridin-2-yl)-N-methylcarbamate
• CAS: 227939-01-7
• 化学式: C₁₁H₁₅BrN₂O₂
• 分子量: 287.156
• InChiKey: YHTZSPWLJTZRDM-UHFFFAOYSA-N

物化性质

• 沸点：
  338.5±27.0 °C(Predicted)
• 密度：
  1.391±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H317,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(N-BOC-N-methylamino)-5-bromopyridine
Synonyms: tert-Butyl 5-bromopyridin-2-yl(methyl)carbamate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(N-BOC-N-methylamino)-5-bromopyridine
CAS number: 227939-01-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H15BrN2O2
Molecular weight: 287.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (5-溴吡啶-2-基)甲基氨基甲酸叔丁酯 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium hydroxide 、 正丁基锂 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 反应 10.33h， 生成 3-[(6-methylamino)pyridin-3-yl]-2,5-dimethyl-N,N-dipropylpyrazolo[1,5-a]pyrimidin-7-amine
  参考文献：
  名称：

  [N-甲基-11C]-3-[(6-二甲氨基)吡啶-3-基]-2,5-二甲基-N,N-二丙基吡唑并[1,5-a]嘧啶-7-胺的合成：A CRF1受体体内成像的潜在PET配体

  摘要：

  [N-甲基-11C]-3-[(6-二甲氨基)吡啶-3-基]-2,5-二甲基-N,N-二丙基吡唑并[1,5-a]嘧啶-7-胺的便捷合成(R121920)，一种高选择性 CRF1 拮抗剂已被开发为潜在的 PET 配体。3 - [(6 - 甲氨基)吡啶 - 3 - 基]-2,5-二甲基-N,N-二丙基吡唑并[1,5-a]嘧啶-7-胺 (7)，用于放射性标记的前体是通过新型钯催化芳基溴 5 与杂芳基硼酸酯 4 的 Suzuki 偶联。所需的硼酸酯 4 由 2-氨基-4-溴吡啶分四步合成，总产率为 50%。尽管冷 R121920 的合成以 93% 的产率通过六甲基二硅叠氮化钠 (NaHMDS) 介导的去甲胺 7 在 -78°C 下进行 N-甲基化，但尝试在各种条件下使用常规碱进行放射合成并没有成功。然而，在不添加碱性试剂的情况下，在-20°C 的丙酮中使用 [11C]MeOTf 成功地对 [11C]R121920

  DOI：

  10.1002/jlcr.738
• 作为产物：
  描述：

  2-氨基-5-溴吡啶 在 sodium hexamethyldisilazane 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 生成 (5-溴吡啶-2-基)甲基氨基甲酸叔丁酯
  参考文献：
  名称：

  [N-甲基-11C]-3-[(6-二甲氨基)吡啶-3-基]-2,5-二甲基-N,N-二丙基吡唑并[1,5-a]嘧啶-7-胺的合成：A CRF1受体体内成像的潜在PET配体

  摘要：

  [N-甲基-11C]-3-[(6-二甲氨基)吡啶-3-基]-2,5-二甲基-N,N-二丙基吡唑并[1,5-a]嘧啶-7-胺的便捷合成(R121920)，一种高选择性 CRF1 拮抗剂已被开发为潜在的 PET 配体。3 - [(6 - 甲氨基)吡啶 - 3 - 基]-2,5-二甲基-N,N-二丙基吡唑并[1,5-a]嘧啶-7-胺 (7)，用于放射性标记的前体是通过新型钯催化芳基溴 5 与杂芳基硼酸酯 4 的 Suzuki 偶联。所需的硼酸酯 4 由 2-氨基-4-溴吡啶分四步合成，总产率为 50%。尽管冷 R121920 的合成以 93% 的产率通过六甲基二硅叠氮化钠 (NaHMDS) 介导的去甲胺 7 在 -78°C 下进行 N-甲基化，但尝试在各种条件下使用常规碱进行放射合成并没有成功。然而，在不添加碱性试剂的情况下，在-20°C 的丙酮中使用 [11C]MeOTf 成功地对 [11C]R121920

  DOI：

  10.1002/jlcr.738

文献信息

• Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS
  作者：Hilary Schenck Eidam、John Russell、Kaushik Raha、Michael DeMartino、Donghui Qin、Huiping Amy Guan、Zhiliu Zhang、Gong Zhen、Haiyu Yu、Chengde Wu、Yan Pan、Gerard Joberty、Nico Zinn、Sylvie Laquerre、Sharon Robinson、Angela White、Amanda Giddings、Ehsan Mohammadi、Beverly Greenwood-Van Meerveld、Allen Oliff、Sanjay Kumar、Mui Cheung

  DOI：10.1021/acsmedchemlett.8b00035

  日期：2018.7.12

  to the discovery of a first-in-class, gut-restricted RET kinase inhibitor, 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-N-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide (15, GSK3179106), as a clinical candidate for the treatment of IBS. GSK3179106 is a potent, selective, and gut-restricted pyridone hinge binder small molecule RET kinase inhibitor with a RET IC50 of

  腹痛和排便习惯异常是肠易激综合症（IBS）患者治疗不当的主要症状。尽管IBS的病因尚不完全清楚，但胃肠道（GI）的许多功能是由肠神经系统（ENS）调节的。炎症或应激诱导的生长因子或细胞因子的表达可能导致胃肠道内脏传入神经元过度神经支配，并有助于IBS的病理生理。转染（RET）期间重新排列的神经元生长因子受体酪氨酸激酶对ENS的发展至关重要，例如Hirschsprung患者携带RET功能丧失突变且缺乏正常的结肠神经支配导致结肠梗阻。相似地，成人ENS中的RET信号通过促进突触形成，信号传递和神经元可塑性来维持神经元功能。ENS中RET的抑制代表了一种新的神经元功能和IBS患者症状正常化的治疗策略。本文中，我们描述了我们的筛选工作以及随后的结构-活性关系（SAR），以优化该系列的效价，选择性和诱变性，从而发现了首屈一指的肠道限制性RET激酶抑制剂2- （4-（4-乙氧基-6-氧代-1,6-二氢
• 噻吩嘧啶类化合物和制剂及其制备方法和应 用
  申请人：广州必贝特医药技术有限公司

  公开号：CN104292242B

  公开（公告）日：2017-05-17

  本发明公开了一种噻吩嘧啶类化合物和制剂及其制备方法和应用，属于化学药物及其制剂技术领域。该噻吩嘧啶类化合物或其药学上可接受的盐，是HDAC(组蛋白脱乙酰酶)/PI3K(磷酸肌醇3‑激酶)双靶点抑制剂，通过选择性抑制具有协同作用的肿瘤细胞信使核心蛋白激酶靶点PI3K和表观遗传靶点HDAC，破坏肿瘤细胞信使网络，从而对各种肿瘤细胞发挥强大的杀灭作用。该抑制剂在多种血液和实体异种移植肿瘤动物模型中，能够强力有效抑制肿瘤生长，尤其在各种血液B‑细胞恶性肿瘤中效果显著，且安全评价实验显示具有良好安全性。可用于淋巴瘤，骨髓瘤和淋巴性白血病晚期复发等或耐药病人的有效治疗。
• [EN] SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE<br/>[FR] INHIBITEURS SÉLECTIFS DE MUTANTS CLINIQUEMENT IMPORTANTS DE LA TYROSINE KINASE DE L'EGFR
  申请人：CS PHARMASCIENCES INC

  公开号：WO2017120429A1

  公开（公告）日：2017-07-13

  The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.

  本发明提供了式（I）的化合物或其亚类结构或种属，或其药学上可接受的盐、酯、溶剂化合物和/或前药，以及用于治疗或改善异常细胞增殖性疾病，如癌症的方法和组合物，其中A、R2、R3、R10、E1、E2、E3、Y和Z如本文所定义。
• [EN] SPIROCYCLIC CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF<br/>[FR] COMPOSÉS CONTENANT DES SPIROCYCLIQUES ET LEURS UTILISATIONS PHARMACEUTIQUES
  申请人：PHARMASCIENCE INC

  公开号：WO2018032104A1

  公开（公告）日：2018-02-22

  The present invention relates to a novel family of covalent kinases inhibitors, compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly ITK and/or TXK, BTK, TEC and/or combinations thereof. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvates of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.

  本发明涉及一种新型的共价激酶抑制剂家族，该类化合物已发现对TEC激酶家族的成员，特别是ITK和/或TXK，BTK，TEC和/或其组合具有抑制活性。本发明涉及一种具有I式结构的化合物或其药学上可接受的盐、溶剂、盐的溶剂体、立体异构体、互变异构体、同位素、前药、复合物或其生物活性代谢物，用于治疗。
• [EN] THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS INHIBITEURS DE LA PI3K À BASE DE THIAZOLOPYRIMIDINE
  申请人：GENENTECH INC

  公开号：WO2009042607A1

  公开（公告）日：2009-04-02

  Compounds of Formulas (Ia and Ib), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  化合物的公式（Ia和Ib），包括立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和其药用可接受的盐，可用于抑制包括PI3K在内的脂质激酶，并用于治疗由脂质激酶介导的癌症等疾病。公开了使用公式Ia和Ib的化合物进行体外、原位和体内诊断、预防或治疗哺乳动物细胞中的这种疾病或相关病理状况的方法。